Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02026232 · ClinicalTrials.gov registry record · NA
Metabolic Effects of Hydroxychloroquine
A NA study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT02026232 is a NA study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 21 participants.
The verdict
NCT02026232, a NA study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
The basic plan of the study is to randomize otherwise healthy subjects with type 2 diabetes to hydroxychloroquine, 200 mg twice daily or placebo.
Interventions
- DRUG Hydroxychloroquine
- OTHER Hydroxychloroquine Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2012-03 |
| Est. Completion | 2022-12-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02026232
The ClinicalTrials.gov registry entry for NCT02026232 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Hydroxychloroquine is the first listed.
NCT02026232 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02026232 about?
NCT02026232 is a clinical study titled "Metabolic Effects of Hydroxychloroquine". The basic plan of the study is to randomize otherwise healthy subjects with type 2 diabetes to hydroxychloroquine, 200 mg twice daily or placebo.
What is the current status of trial NCT02026232?
This trial is currently terminated. It is a NA study. The enrollment target is 21 participants. The study started on 2012-03. Estimated completion is 2022-12-15.
What interventions are being tested in trial NCT02026232?
The interventions under investigation include: Hydroxychloroquine (DRUG), Hydroxychloroquine Placebo (OTHER).
Who is sponsoring clinical trial NCT02026232?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.